All Stories

  1. ALEMTUZUMAB (CAMPATH-1H) INDUCTION AND PREDNISONE - FREE MAINTENANCE IMMUNOTHERAPY IN KIDNEY TRANSPLANT HISPANIC PATIENTS

    Article • Transplantation, July 2010, Wolters Kluwer Health

    Fernando Giron

  2. Critical appraisal on the use of everolimus in renal transplantation as an immunosuppressant to prevent organ transplant rejection

    Article • Transplant Research and Risk Management, January 2010, Taylor & Francis

    Fernando Giron

  3. Experience With Alemtuzumab (Campath-1H) as Induction Agent in Renal Transplantation Followed by Steroid-Free Immunosuppression

    Article • Transplantation Proceedings, April 2008, Elsevier

    Fernando Giron

  4. Use of Nonabsorbable Polymer Ligaclip in Hand-Assisted Laparoscopic Nephrectomy for Living Donor

    Article • Transplantation Proceedings, April 2008, Elsevier

    Fernando Giron

  5. Conversion Therapy to Everolimus in Renal Transplant Recipients: Results After One Year

    Article • Transplantation Proceedings, April 2008, Elsevier

    Fernando Giron

  6. Organ Donation in Latin America

    Article • Transplantation Proceedings, March 2007, Elsevier

    Fernando Giron

  7. SAFETY ASSESSMENT OF THE CONVERSION FROM MYCOPHENOLATE MOFETIL TO MYCOPHENOLATE SODIUM IN STABLE RENAL TRANSPLANT RECIPIENTS. FULL DOSE TOLERABILITY WITH ENTERIC COATED MYCOPHENOLATE SODIUM

    Article • Transplantation, July 2004, Wolters Kluwer Health

    Fernando Giron

  8. LATINAMERICAN STUDY ABOUT THE SAFETY AND TOLERABILITY OF THE CONVERSION TO ENTERIC-COATED MYCOPHENOLATE SODIUM FROM MYCOPHENOLATE MOFETIL IN STABLE RENAL RECIPIENTS

    Article • Transplantation, July 2004, Wolters Kluwer Health

    Fernando Giron

  9. Stable renal transplant recipients can be safely converted from MMF to enteric-coated mycophenolate sodium tablets: Interim results of a multicenter Latin American study

    Article • Transplantation Proceedings, July 2004, Elsevier

    Fernando Giron